Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Oramed Pharm ( (ORMP) ) has provided an update.
On January 7, 2026, Oramed Pharmaceuticals reported receiving an $18 million payment from Scilex Holdings Inc., marking full satisfaction of obligations under their Option Agreement and lifting Oramed’s realized returns on its original $99.5 million Scilex investment to $118 million. The company continues to hold a $27 million note and a $12 million convertible note in Scilex, along with warrants and a nine-year royalty interest, leaving further potential upside from the relationship and underscoring Oramed’s strategy of leveraging investment gains alongside its clinical operations. Reflecting these gains and surplus capital, Oramed’s board approved a cash dividend of $0.25 per share, expected to distribute about $10.5 million to shareholders on January 26, 2026, to investors of record as of January 16, 2026, signaling confidence in the company’s financial position and providing a direct return to equity holders.
The most recent analyst rating on (ORMP) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Oramed Pharm stock, see the ORMP Stock Forecast page.
Spark’s Take on ORMP Stock
According to Spark, TipRanks’ AI Analyst, ORMP is a Neutral.
The score is driven mainly by mixed fundamentals: strong balance-sheet leverage position but weak operating performance and ongoing cash burn. Technicals are moderately constructive with price above key moving averages, valuation looks favorable based on the low P/E, and corporate events improve liquidity and signal shareholder-friendly actions.
To see Spark’s full report on ORMP stock, click here.
More about Oramed Pharm
Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company developing oral delivery solutions for drugs traditionally administered by injection, based on its proprietary Protein Oral Delivery (POD) technology. Alongside advancing its refined oral insulin program, the company is also building a diversified active investment portfolio to complement its core drug delivery platform.
Average Trading Volume: 180,256
Technical Sentiment Signal: Hold
Current Market Cap: $117.8M
For a thorough assessment of ORMP stock, go to TipRanks’ Stock Analysis page.